Preclinical

The goal of ACTIV is to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and treatments.

Overview

The Preclinical Working Group is focused on:

  • Establishing a centralized process and repository for harmonizing and sharing methods and evaluating animal models
  • Extending access to high-throughput screening facilities, especially in biosafety level 3 (BSL-3) labs
  • Increasing access to validated animal models
  • Enhancing comparison of approaches to identify informative assays
  • Generating a process to assess viral variant effects on vaccines and therapeutics

Learn more

TRACE  Initiative

The Tracking Resistance and Coronavirus Evolution (TRACE) initiative is focused on:

  • Monitoring global emergence and circulation of SARS-CoV-2 mutations
  • Cross-referencing initial sequence data against database of experimentally or clinically phenotyped mutants
  • Characterizing prioritized mutants in vitro through critical-path assays
  • Characterizing prioritized mutants in vivo through critical-path assays
  • Rapidly sharing activity data with ACTIV and scientific community

Learn more

Announcing
"Long COVID” Seminar Series

The ACTIV Preclinical Working Group, in partnership with the National Heart, Lung, and Blood Institute (NHLBI), hosted an expert-led seminar series on post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID.